OTCMKTS:MEOBF Mesoblast (MEOBF) Stock Price, News & Analysis → Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad) Free MEOBF Stock Alerts $0.60 0.00 (0.00%) (As of 04/19/2024 ET) Add Compare Share Share Today's Range$0.60▼$0.6050-Day Range$0.17▼$0.6052-Week Range$0.10▼$1.00VolumeN/AAverage Volume359,867 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsShort InterestStock AnalysisChartFinancialsSEC FilingsShort Interest Get Mesoblast alerts: Email Address Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Mesoblast Stock (OTCMKTS:MEOBF)Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Read More MEOBF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEOBF Stock News HeadlinesMarch 11, 2024 | benzinga.comWhy Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day SessionDecember 26, 2023 | markets.businessinsider.comJefferies Keeps Their Buy Rating on Mesoblast Limited (MEOBF)April 19, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.December 25, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Guangzhou Baiyunshan Pharmaceutical Holdings Company (GZPHF), Mesoblast Limited (MEOBF)December 9, 2023 | morningstar.comMesoblast Ltd ADR MESOJanuary 11, 2023 | finance.yahoo.comMesoblast Limited (MEOBF) Stock Historical Prices & Data - Yahoo FinanceSeptember 29, 2022 | reuters.comMESO.O - Mesoblast limited (ADR) | Stock Price & Latest News | ReutersSeptember 29, 2022 | investing.comMesoblast Teva StartsApril 19, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.September 1, 2022 | seekingalpha.comMesoblast Limited (MESO) Q4 2022 Earnings Call TranscriptSeptember 1, 2022 | seekingalpha.comMesoblast Limited 2022 Q4 - Results - Earnings Call PresentationMay 25, 2022 | markets.businessinsider.comMindMed Appoints Schond L. Greenway As CFOMay 25, 2022 | benzinga.comMesoblast (OTC:MEOBF), Short Interest ReportMay 25, 2022 | benzinga.comMesoblast (OTC:MEOBF), Earnings Estimates, EPS, and RevenueApril 29, 2022 | seekingalpha.comMesoblast reports FQ3 resultsMarch 28, 2022 | fool.comMesoblast Limited (MESO) Q1 2022 Earnings Call TranscriptAugust 31, 2021 | markets.businessinsider.comWhy Mesoblast Stock Is Plunging After Q4 Earnings Report?August 24, 2021 | finance.yahoo.comLoss-Making Mesoblast Limited (ASX:MSB) Expected To Breakeven In The Medium-TermSee More Headlines Receive MEOBF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:MEOBF CUSIPN/A CIK1345099 Webwww.mesoblast.com Phone(139) 639-6036FaxN/AEmployees83Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Silviu Itescu FACP (Age 67)FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director Comp: $738.74kDr. Eric A. Rose M.D. (Age 73)Chief Medical Officer & Executive Director Comp: $625.46kMr. Andrew Chaponnel B.Com.Interim Chief Finance OfficerMr. Peter T. Howard B.Sc. (Age 56)L.L.B., LLB (Hons), General Counsel & Corporate Executive Mr. Roger D. Brown BAHead of Spinal Orthopedic DisordersMr. Michael Schuster BSc (Age 47)M.B.A., MS, Head of Pharma Partnering Ms. Geraldine Storton B.Sc.M.B.A., MMS, Head of Regulatory Affairs & Quality ManagementMr. Justin Horst B.S.Head of ManufacturingMs. Niva Sivakumar B.Com.L.L.B., Joint Company SecretaryMr. Paul Hughes BPHARMJoint Company SecretaryMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors MEOBF Stock Analysis - Frequently Asked Questions How have MEOBF shares performed in 2024? Mesoblast's stock was trading at $0.1667 at the start of the year. Since then, MEOBF stock has increased by 259.9% and is now trading at $0.60. View the best growth stocks for 2024 here. Are investors shorting Mesoblast? Mesoblast saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 150,500 shares, an increase of 1,319.8% from the March 15th total of 10,600 shares. Based on an average daily trading volume, of 154,300 shares, the days-to-cover ratio is currently 1.0 days. View Mesoblast's Short Interest. How do I buy shares of Mesoblast? Shares of MEOBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MEOBF) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTISHOCKING Crypto Leak…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceOptions trading has suddenly become more reliable.Eagle PublishingHow Biden has already won 2024Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.